Maca T, Fasching P, Rohac M, Stur M, Schneider B, Waldhäusl W
Klinische Abteilung für Endokrinologie und Stoffwechsel Universitätsklinik für Innere Medizin III, Wien.
Dtsch Med Wochenschr. 1996 Mar 1;121(9):257-62. doi: 10.1055/s-2008-1043002.
To assess prospectively the effect of improving the metabolic state on the course of diabetic retinopathy in relation to the extent of retinal changes before intervention.
140 patients with type I (insulin-dependent) diabetes mellitus (IDDM) (55 men, 85 women; mean age 30 +/- 11 years; mean duration of illness 11 +/- 8 years), underwent intensified insulin treatment and were then followed for 4 years. At the beginning of the trial fundoscopy was unremarkable in 68 patients (stage 0), a few microaneurysms and (or) punctate bleeding (stage 1) in 21, nonproliferative retinopathy (stage 2) in 27, preproliferative retinopathy (stage 3) in six, proliferative retinopathy (stage 4) in 14, and proliferative retinopathy with complications (stage 5) in four. The average retinopathy stage was 1.2 +/- 1.0, mean HbA1c value 7.0 +/- 1.3%).
The retinopathy remained unchanged in 94 patients (group A), it improved in 16 (group B), and deteriorated in 30 (group C). There was no significant change in mean HbA1c value in any of the groups (A: 6.2 +/- 0.9%; B: 6.4 +/- 1.0%; C: 6.3 +/- 6.0%). There were also no differences with respect to blood glucose, M-value according to Schlichtkrull, frequency of hypoglycaemia, serum lipids, blood pressure and renal biopsy parameters. However, significant differences (P < 0.001 C vs. A and B) were found in relation to duration of diabetes (A: 9.3 +/- 7.2 years; B: 8.8 +/- 8.6 years; C: 16.9 +/- 7.8 years) and mean retinopathy stage at beginning of the study (A: 0.8 +/- 0.8; B: 1.2 +/- 0.7; C: 2.4 +/- 1.6).
Decisive for the course of retinopathy in patients with IDDM of long duration and secondarily optimised metabolic state is the duration of illness and especially the degree of fundal changes when intensified insulin treatment is undertaken.
前瞻性评估改善代谢状态对糖尿病视网膜病变病程的影响,并分析其与干预前视网膜病变程度的关系。
140例1型(胰岛素依赖型)糖尿病(IDDM)患者(男性55例,女性85例;平均年龄30±11岁;平均病程11±8年)接受强化胰岛素治疗,随后随访4年。试验开始时,68例患者眼底检查正常(0期),21例有少量微动脉瘤和(或)点状出血(1期),27例为非增殖性视网膜病变(2期),6例为增殖前期视网膜病变(3期),14例为增殖性视网膜病变(4期),4例为伴有并发症的增殖性视网膜病变(5期)。视网膜病变平均分期为1.2±1.0,平均糖化血红蛋白(HbA1c)值为7.0±1.3%。
94例患者视网膜病变无变化(A组),16例改善(B组),30例恶化(C组)。各组的平均HbA1c值均无显著变化(A组:6.2±0.9%;B组:6.4±1.0%;C组:6.3±6.0%)。血糖、根据施利希特克鲁尔法测得的M值、低血糖发生频率、血脂、血压及肾活检参数方面也无差异。然而,在糖尿病病程(A组:9.3±7.2年;B组:8.8±8.6年;C组:16.9±7.8年)和研究开始时的平均视网膜病变分期(A组:0.8±0.8;B组:1.2±0.7;C组:2.4±1.6)方面,发现有显著差异(C组与A组及B组相比,P<0.001)。
对于病程较长且代谢状态已得到二次优化的IDDM患者,视网膜病变的病程取决于患病时长,尤其是在进行强化胰岛素治疗时眼底病变的程度。